Technical Analysis for ALKS - Alkermes plc

Grade Last Price % Change Price Change
grade C 18.81 1.07% 0.20
ALKS closed up 1.07 percent on Thursday, August 13, 2020, on 50 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Up
Historical ALKS trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Spinning Top Other 0.00%
Narrow Range Bar Range Contraction 1.07%
Inside Day Range Contraction 1.07%
50 DMA Resistance Bearish 3.35%
Fell Below 50 DMA Bearish 1.27%
200 DMA Support Bullish 1.27%
Hammer Candlestick Bullish 1.27%
50 DMA Support Bullish 0.62%
Spinning Top Other 0.62%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA/ FAMPYRA for the treatment of multiple sclerosis; BYDUREON for the treatment of type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for severe pain; EMEND for the treatment of nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES for the treatment of cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE for the prevention of renal transplant rejection; NAPRELAN for various mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFE Ditab CR for hypertension; and DILZEM SR, DILZEM XL, DILTELAN, ACALIX CD, DINISOR, TILAZEM CR, and CARDIZEM CD for hypertension and/or angina. In addition, it develops ALKS 9070, which is in phase 3 study for the treatment of schizophrenia; ALKS 37 that is under phase 2b study for the treatment of opioid-induced constipation; ALKS 33, which has completed phase 2 study for modulation of brain opioid receptors; ALKS 5461 that is under phase 2 study for the treatment of depressive disorder, as well as under phase 1b study for the treatment of cocaine dependence; and ZOHYDRO for pain relief. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration with Janssen Pharmaceutica N.V. for the development of RISPERDAL CONSTA. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Chemistry Biopharmaceutical Pain Surgery Chemotherapy Multiple Sclerosis Schizophrenia Organic Chemistry Hypertension Morphinans Neurochemistry Nausea Obsessive Compulsive Disorder Ii Diabetes Angina Depressive Disorder Opioid Antagonists Pharmaceutical Wholesalers Treatment Of Multiple Sclerosis AIDS Atypical Antipsychotics Opioid Induced Constipation Renal Transplant

Is ALKS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 23.22
52 Week Low 11.98
Average Volume 1,451,622
200-Day Moving Average 18.15
50-Day Moving Average 18.73
20-Day Moving Average 19.10
10-Day Moving Average 18.57
Average True Range 0.70
ADX 20.43
+DI 17.85
-DI 23.53
Chandelier Exit (Long, 3 ATRs ) 18.74
Chandelier Exit (Short, 3 ATRs ) 19.79
Upper Bollinger Band 20.51
Lower Bollinger Band 17.69
Percent B (%b) 0.4
BandWidth 14.76
MACD Line -0.11
MACD Signal Line -0.01
MACD Histogram -0.0976
Fundamentals Value
Market Cap 2.89 Billion
Num Shares 154 Million
EPS -1.29
Price-to-Earnings (P/E) Ratio -14.58
Price-to-Sales 10.50
Price-to-Book 7.03
PEG Ratio -1145.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.42
Resistance 3 (R3) 19.40 19.17 19.32
Resistance 2 (R2) 19.17 19.02 19.18 19.28
Resistance 1 (R1) 18.99 18.92 19.08 19.01 19.25
Pivot Point 18.77 18.77 18.81 18.78 18.77
Support 1 (S1) 18.59 18.61 18.68 18.61 18.37
Support 2 (S2) 18.36 18.51 18.37 18.34
Support 3 (S3) 18.18 18.36 18.30
Support 4 (S4) 18.20